Ultragenyx Pharmaceutical's market cap is currently ―. The company's EPS TTM is $-8.33; its P/E ratio is -5.60; Ultragenyx Pharmaceutical is scheduled to report earnings on May 2, 2024, and the estimated EPS forecast is $-1.76. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 98.05M	$ 46.33M	$ 100.50M	$ 103.35M	$ 90.70M
Gross Profit	$ 98.05M	$ 108.31M	$ 100.50M	$ 60.33M	$ 82.07M
EBIT	$ -159.00M	$ -159.10M	$ -163.48M	$ -173.99M	$ -224.31M
EBITDA	-	$ -156.95M	$ -161.24M	$ -180.04M	$ -219.62M
Net Income Common Stockholders	$ -120.01M	$ -159.83M	$ -163.97M	$ -151.83M	$ -245.11M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 442.09M	$ 551.98M	$ 629.35M	$ 747.76M	$ 888.67M
Total Assets	$ 1.24B	$ 1.31B	$ 1.38B	$ 1.29B	$ 1.62B
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 34.68M
Net Debt	$ -442.09M	$ -551.98M	$ -629.35M	$ -747.76M	$ -853.99M
Total Liabilities	$ 1.21B	$ 1.18B	$ 1.16B	$ 1.55B	$ 1.15B
Stockholders Equity	$ 31.71M	$ 129.03M	$ 220.48M	$ 352.49M	$ 468.83M
Cash Flow	-
Free Cash Flow	-	$ -132.60M	$ -181.90M	$ -117.31M	$ -121.39M
Operating Cash Flow	$ -117.87M	$ -116.16M	$ -156.87M	$ -90.34M	$ -95.34M
Investing Cash Flow	$ 64.30M	$ 99.42M	$ 111.30M	$ -171.60M	$ -161.86M
Financing Cash Flow	$ 25.23M	$ 33.01M	$ -722.00K	$ 1.88M	$ 491.88M

Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History

Income Statement >

Ultragenyx Pharmaceutical Debt to Assets

Balance Sheet >

Ultragenyx Pharmaceutical Cash Flow

Cash Flow >

Ultragenyx Pharmaceutical Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing